Obesity has an impact on COVID-19 susceptibility and severity: a two-sample Mendelian randomization study

Dennis Freuer[1,2], Jakob Linseisen[1,2], Christa Meisinger[1,2]

1: Chair of Epidemiology at UNIKA-T Augsburg, Ludwig-Maximilians-University of Munich, 86156 Augsburg, 80539 Munich, Germany

2: Independent Research Group Clinical Epidemiology, Helmholtz Center Munich, German Research Centre for Environmental Health, 85764 Neuherberg, Germany

ABSTRACT

Background

Recent observational studies suggested obesity to be a possible risk factor for COVID-19 disease in the wake of the coronavirus (SARS-CoV-2) infection. However, the causality as well as the role of body fat distribution in this context still unclear. Thus, using a two-sample Mendelian randomization (MR) approach, we investigated the causal impact of obesity on the susceptibility and severity of COVID-19.

Methods

Obesity was quantified by body mass index (BMI), waist circumference (WC), and waist-to-hip ratio (WHR). Summary statistics of genome-wide association studies (GWASs) for these anthropometric measures were drawn from the GIANT consortium (Locke et al. (n=322154); Shungin et al. (n=232101)) and for the COVID-19 susceptibility (n=1079768) as well as hospitalization (n = 900687) from the COVID-19 Host Genetics Initiative. Causal estimates were calculated using Single Nucleotide Polymorphisms (SNPs) and sensitivity analyses were done applying several robust MR techniques.

Results

Genetically predicted BMI was significantly associated (per one SD) with both, COVID-19 susceptibility (OR=1.41; 95% CI: 1.15 – 1.72; P-value=0.001) and hospitalization (OR=1.60; 95% CI: 1.19 – 2.14; P-value=0.006). WC was associated with the susceptibility (OR=1.38; 95% CI: 1.07 – 1.78; P-value=0.015) but not with hospitalization. WHR was not associated with any of the COVID-19 outcomes.

Conclusions

This study provides evidence for a causal impact of overall obesity on the susceptibility and severity of COVID-19. Therefore, obese people should be regarded as a risk group. Future research is necessary to investigate the underlying mechanisms linking obesity with COVID-19.

INTRODUCTION

At the end of 2019, there was an outbreak of a coronavirus infection (SARS-CoV-2), which is partly associated with very severe disease courses; this COVID-19 outbreak developed into a pandemic within a short period of time(1). This pandemic with currently more than ten million infected subjects and a high number of deaths requires the study of risk factors associated with a higher susceptibility to the virus or a more severe course of the disease to identify high risk groups that require special protection.

As consequence of the 2009 H1N1 influenza A virus pandemic, obesity was identified for the first time as a risk factor for increased disease severity and mortality in infected individuals(2; 3). These observations have led to the assumption that obese people may be vulnerable to a more severe COVID-19 disease course. Very recent, observational studies confirm that obesity could be a risk factor for hospitalization with COVID-19 and also a significant predictor for mortality among inpatients with this infection(4-6).

This is in line with previous studies suggesting obesity as an independent predictor of infectious diseases, such as blood stream infection, urinary infections, respiratory infections, and skin infections(7). However, so far, research on the causal role of obesity on the susceptibility to SARS-CoV-2 and severity of the disease is missing.

A Mendelian randomization approach offers the possibility to examine causality by using genetic variants as instruments, which are explicitly associated with the exposure. Thus, it is possible to minimize confounding and preclude reverse causation because variants are randomly allocated from parents to offspring at conception. In this study we investigated causal effects of BMI, waist circumference (WC), and waist-hip-ratio (WHR) on the risk of SARS-CoV-2 infection and severe course of COVID-19 disease.

METHODS

Study design

In a two-sample Mendelian randomization (MR) approach genetic variants were used to assess causal effects of obesity as a modifiable risk factor on COVID-19 susceptibility and hospitalization as a consequence of an infection with the SARS- CoV-2 virus. Details on the MR-design were described elsewhere(8-10).

Obesity measurements and data availability

To quantify obesity and assess body fat distribution we used three different anthropometric measures, namely BMI, WC, and WHR. For BMI the summary statistics of genome-wide association studies (GWASs) of Locke et al.(11) (n = 322 154) and for WC as well as WHR of Shungin et al.(12) (n = 232 101) were used. These studies arose from the GIANT consortium that includes observations in men and women of European ancestry [Supplemental Table S1]. In all original studies, ethical approval had been obtained.

Selection of genetic instrumental variables for anthropometric measures

Due to the genome-wide significance threshold of $P < 5 \times 10^{-8}$ 69 BMI-related, 42 WC-related and 29 WHR-related independent SNPs were considered for MR analyses [Supplemental Table S1]. In case of BMI and WC the SNP rs1558902 and for WHR the SNP rs9491696 were removed due to being palindromic with intermediate allele frequencies. The remaining 68, 41, and 28 SNPs explained overall 1.3 %, 0.9 %, and 0.6 % of the variance in BMI, WC, and WHR, respectively. None of the instrumental SNPs were excluded due to a genome-wide significant association with any of the outcomes or with possible confounding factors after conducting a PhenoScanner search [Supplemental Tables S2-4].

GWAS summary statistics for COVID-19 disease

Genetic associations with COVID-19 susceptibility and hospitalization were acquired from the growing COVID-19 Host Genetics Initiative(13), which provide publicly accessible summary statistics of genome-wide association studies in relation to several COVID-19 outcomes from different studies (e.g. UK Biobank, FinnGen). In the third release from June 29, 2020 in total 6696 positive tested COVID-19 cases (vs. 1073072 controls) and 3199 hospitalized COVID-19 patients due to severe symptoms (vs. 897488 controls) were available. Further information and new releases can be taken from the COVID-19 Host Genetics Initiative(13) homepage.

Selection of genetic instruments for obesity

As independent instruments we considered SNPs that were associated with an exposure (BMI, WC, WHR) at the genome-wide significance threshold $P < 5 \times 10^{-8}$ and were not in linkage disequilibrium (LD) using a clumping procedure with the cut-off $r^2 = 0.001$.

Statistical power

The a priori statistical power for the binary traits susceptibility and hospitalization due to COVID-19 disease was calculated according to Burgess et al.(14). According to Supplemental Table S5, where the explained phenotypic variances are between 0.60 % for WHR and 1.3 % for BMI. Given a type I error of 5 %, our analyses were sufficiently powered ($\geq$ 80 %) when the expected OR per one standard deviation of the respective anthropometric measure for SARS-CoV-2 infection and hospitalization was $\geq$ 1.5 in genetically instrumented BMI/WC/WHR.

Statistical analyses

Causal estimates of the relationship between anthropometric measures and Covid-19 susceptibility as well as hospitalization were calculated, applying an inverse-variance weighted (IVW) meta-analysis using modified second order weights within the radial regression framework. This approach provides the highest statistical power if the key assumptions of the Mendelian randomization are met. To assess and validate these assumptions we performed several sensitivity analyses that consider different patterns of violations. Among others, we used the MR-PRESSO (Pleiotropy RESidual Sum and Outlier) method for two issues: the global test detected (based on observed residual sum of squares) horizontal pleiotropy and the outlier test identified potential outlier SNPs at a threshold of 0.05 [Supplemental Table S6].

Under the Instrument Strength Independent of Direct Effect (InSIDE) assumption, the radial MR-Egger intercept test was used for assessing directional pleiotropy. Substantial heterogeneity within the IVW and MR-Egger methods was quantified and tested using Cochran's as well as Rücker's Q statistics [Supplemental Table S7]. If necessary, we moved from fixed to random effects models that account for balanced horizontal and directional pleiotropy, respectively. Furthermore, we investigated influential SNPs based on the respective Q statistic and several plots (e.g. radial, funnel, leave-one-out, and SNP-exposure-outcome association plots).

To assess consistency of causal estimates in case of horizontal pleiotropy as well as outlier occurrence, we additionally performed three types of robust estimation methods. The first was the weighted median approach that requires at least 50 % of the genetic variants to be valid instruments. The second was the weighted mode method, which is consistent even if less than 50 % of the genetic variants are valid. Third, we conducted a many weak instruments

analysis using the RAPS (Robust Adjusted Profile Score) method and controlled for systematic pleiotropy in form of overdispersion, if necessary.

After application of the Bonferroni correction to account for multiple testing issues, P-values with P < 0.008 were considered statistically significant and values of 0.008 ≤ P < 0.05 as suggestive significant. All reported ORs were expressed per one standard deviation increment of each body composition measure. Significance thresholds were set to α = 0.01 for testing the Q statistics and α = 0.05 for the PRESSO global test. Analyses were performed using primarily the TwoSampleMR (version 0.5.4) and MRPRESSO (version 1.0) packages of the statistical Software R (version: 4.0.0).

RESULTS

Genetically predicted BMI was significantly positively associated with both, COVID-19 susceptibility (OR = 1.41; 95 % CI: 1.15 – 1.72; P-value = 0.001) and hospitalization (OR = 1.60; 95 % CI: 1.19 – 2.14; P-value = 0.006) due to severe symptoms of COVID-19 [Tables 1-2]. Furthermore, there was suggestive evidence that WC was associated with COVID-19 susceptibility (OR = 1.38; 95 % CI: 1.07 – 1.78; P-value = 0.015) but not with hospitalization (OR = 1.47; 95 % CI: 0.97 – 2.23; P-value = 0.069) due to COVID-19. Beyond that, there was no causal relationship between genetically predicted anthropometric measures and both COVID-19 outcomes [Figure 1].

Although Cochran's Q_j statistic for a particular SNP revealed one outlier (rs12549058, Cochran's Q_j = 7.42; P-value = 0.006) for the association between WHR and COVID-19 susceptibility, the exclusion of this variant had not a substantial effect on the appropriate estimate [Figure 1]. Regarding Cochran's Q and Rücker's Q' statistics as well as the differences Q-Q' with $P_{min} > 0.11$ and the ratios $\frac{Q'}{Q} \approx 1$ there was no evidence for any pleotropic effect [Supplemental Table S7]. Additionally, neither MR-PRESSO global tests nor the radial MR-Egger intercept tests indicated horizontal or directional pleiotropy, respectively [Supplemental Table S6]. Therefore, all of the causal estimates above (representing the magnitude of the effect of one standard deviation in the anthropometric measures) were obtained by the radial IVW model using modified second order weights. The estimated causal effects by the radial method were equal to those of the standard IVW method with multiplicative random effects. Except in case of WHR, where no evidence for a causal relationship was found, the robust methods led to consistent results (suggested mostly significant positive SNP-outcome associations) supporting the findings revealed by the radial IWV models [Tables 1-2]. Especially the

robust RAPS, and PRESSO models led to the same decisions as the IVW approach. Beyond that, overdispersion could not be detected within the RAPS method.

DISCUSSION

The present study using genetic instruments for BMI, WC, and WHR from publicly available large-scale GWAS provides evidence for a causal role of general and abdominal obesity regarding SARS-CoV-2 susceptibility and disease severity.

In addition to the recently published observational studies assuming that obesity might be an independent risk factor for COVID-19, the results of the present MR-analysis clearly indicated a causal role. A number of observational studies have investigated whether and what role obesity plays in the context of the current COVID-19 pandemic. For example, a French investigation regarding the prevalence of obesity among inpatients with COVID-19 showed that the prevalence of obesity was higher in critical ill COVID-19 patients in comparison to non-critical cases (OR = 1.96; 95 % CI: 1.13-3.42) even after multivariable adjustment(15; 16). A study from New York City including 4 103 patients suffering from COVID-19 reported that a BMI > 40 kg/m² was the strongest predictor after old age for hospitalization due to COVID-19(5). In a prospective cohort study based on the ISARIC WHO Clinical Characterization Protocol including 16 749 hospitalized patients, it was found that 17% of the patients needed critical care. Being elderly, male and obese were associated with adverse outcomes(4). In that study, obese patients had a HR of 1.37 (95 % CI 1.16 – 1.63) for death after adjustment for age and sex in the analysis. Another cohort study based on linked electronic health records of 17 million adult NHS patients reported an increased in-hospital mortality risk due to COVID-19 for obese patients even after multivariable adjustment (HR of 1.27 for BMI 30 – 34.9 kg/m² and a HR of 2.27 for BMI >=40 kg/m2)(6).

Several mechanisms may explain why obese people are at increased risk for COVID-19 infection. Inflammation and the immune system in obese individuals could play a role in relation to viral diseases. In adipose tissue there is a high production of pro-inflammatory cytokines causing chronic low-grade inflammation and immune dysregulation(17; 18). Results from animal models revealed that the role of obesity in increasing the risk of influenza morbidity and mortality is due to the impairment of the immune response to this pathogen(19). Green et al. proposed that hyperinsulinemia or hyperleptinemia which occurs predominantly in obese subjects may lead to a metabolic dysregulation of T cells, resulting in an impairment of the activation and function of these adaptive immune cells in response to influenza

viruses(19). In this context, Honce et al. emphasized especially the role of visceral adiposity(20). Which metabolic and immune derangements in obese people are responsible for the increased susceptibility to SARS-CoV-2 infections should be subject of further research.

In connection with COVID-19 it is discussed that the SARS-CoV receptor ACE2 is also used by the SARS-CoV-2 spike protein (a special surface glycoprotein) as a cellular entry receptor(21). In human tissue ACE2 is expressed in the lung, the main target site for COVID-19 infection, but also in extrapulmonary tissues including heart, kidney, and intestine. Furthermore, obesity upregulates ACE2 receptor and therefore obese subjects have larger amounts of ACE2(22). It can be assumed that analogous to SARS-CoV(23), excessive ACE2 may competitively bind with SARS-CoV-2 not only to neutralize the virus but also rescue cellular ACE2 activity which negatively regulates the renin-angiotensin system to protect the lung from injury(24). Through the downregulation of ACE2 activity angiotensin II, the substrate for ACE, will accumulate and lead to increased neutrophil accumulation, increased vascular permeability, and pulmonary oedema, which will lead to severe lung injury. Because obesity is associated with a dysregulation of the renin-angiotensin-aldosterone system and thus among other things linked to an overexpression of angiotensin II(25). This represent an important link between obesity and severity of COVID-19.

Strengths of the study include that we performed a range of robust MR methods to conduct sensitivity analyses for different patterns of pleiotropy. The use of three anthropometric measures, that have different views on body fat distribution, allowed us to compare as well as differentiate between overall obesity and body fat distribution as exposures. Furthermore, they strengthened evidence by reciprocal verification. However, our study also has limitations. The relationship between obesity and the risk of acquiring COVID-19 disease is influenced by selection bias, because people with no, uncomplicated or milder symptoms often were not tested regarding SARS-CoV-2 infection. This causes bias towards the null hypothesis due to false negatives (type II error) and reduces therefore the power by underestimating the true causal effect. Sex-specific samples would lead to higher precision, although we did not expect large differences between men and women. Furthermore, the present study was conducted in subjects of European ancestry and therefore the findings could not be applied to other ethnicities.

Our study is the first strengthening the evidence that overall and abdominal obesity is causally associated with the susceptibility to and the severity of SARS-CoV-2 virus infections. Future research is necessary to investigate the underlying mechanisms linking (abdominal) obesity with COVID-19. Since the prevalence of obesity is still increasing in many countries and the probability of emerging and re-emerging infectious diseases might be high in the future

(26), intensive public health interventions targeting obesity are necessary to reduce morbidity and mortality due to infectious diseases such as COVID-19.

Funding

The authors did not receive funding for this study. Funding information of the genome-wide association studies is specified in the cited studies.

Conflict of interest

All authors declare that they have nothing to disclose.

Data availability

The present study is based on summary-level data that have been made publically available. Summary data from genome-wide association studies for the BMI (Locke et al.), WC, and WHR (Shungin et al.) are available at https://portals.broadinstitute.org/collaboration/giant/index.php/GIANT_consortium_data_files. The COVID-19 GWAS summary data are available at https://www.covid19hg.org/results. In all original studies, ethical approval had been obtained.

REFERENCES

1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W, China Novel Coronavirus I, Research T. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med 2020;382:727-733

2. Sun Y, Wang Q, Yang G, Lin C, Zhang Y, Yang P. Weight and prognosis for influenza A(H1N1)pdm09 infection during the pandemic period between 2009 and 2011: a systematic review of observational studies with meta-analysis. Infect Dis (Lond) 2016;48:813-822

3. Van Kerkhove MD, Vandemaele KA, Shinde V, Jaramillo-Gutierrez G, Koukounari A, Donnelly CA, Carlino LO, Owen R, Paterson B, Pelletier L, Vachon J, Gonzalez C, Hongjie Y, Zijian F, Chuang SK, Au A, Buda S, Krause G, Haas W, Bonmarin I, Taniguichi K, Nakajima K, Shobayashi T, Takayama Y, Sunagawa T, Heraud JM, Orelle A, Palacios E, van der Sande MA, Wielders CC, Hunt D, Cutter J, Lee VJ, Thomas J, Santa-Olalla P, Sierra-Moros MJ, Hanshaoworakul W, Ungchusak K, Pebody R, Jain S, Mounts AW. Risk factors for severe outcomes following 2009 influenza A (H1N1) infection: a global pooled analysis. PLoS Med 2011;8:e1001053

4. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, Holden KA, Read JM, Dondelinger F, Carson G, Merson L, Lee J, Plotkin D, Sigfrid L, Halpin S, Jackson C, Gamble C, Horby PW, Nguyen-Van-Tam JS, Dunning J, Openshaw PJ, Baillie JK, Semple MG. Features of 16,749 hospitalised UK patients with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol. medRxiv 2020:2020.2004.2023.20076042

5. Petrilli CM, Jones SA, Yang J, Rajagopalan H, O'Donnell LF, Chernyak Y, Tobin K, Cerfolio RJ, Francois F, Horwitz LI. Factors associated with hospitalization and critical illness among 4,103 patients with COVID-19 disease in New York City. medRxiv 2020:2020.2004.2008.20057794

6. Williamson E, Walker AJ, Bhaskaran KJ, Bacon S, Bates C, Morton CE, Curtis HJ, Mehrkar A, Evans D, Inglesby P, Cockburn J, Mcdonald HI, MacKenna B, Tomlinson L, Douglas IJ, Rentsch CT, Mathur R, Wong A, Grieve R, Harrison D, Forbes H, Schultze A, Croker RT, Parry J, Hester F, Harper S, Perera R, Evans S, Smeeth L, Goldacre B. OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients. medRxiv 2020:2020.2005.2006.20092999

7. Bercault N, Boulain T, Kuteifan K, Wolf M, Runge I, Fleury JC. Obesity-related excess mortality rate in an adult intensive care unit: A risk-adjusted matched cohort study. Crit Care Med 2004;32:998-1003

8. Burgess S, Foley CN, Zuber V. Inferring Causal Relationships Between Risk Factors and Outcomes from Genome-Wide Association Study Data. Annu Rev Genomics Hum Genet 2018;19:303-327

9. Davies NM, Holmes MV, Davey Smith G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ 2018;362:k601

10. Burgess S, Thompson SG. *Mendelian randomization : methods for using genetic variants in causal estimation*. Boca Raton, CRC Press, Taylor & Francis Group, 2015

11. Locke AE, Kahali B, Berndt SI, Justice AE, Pers TH, Day FR, Powell C, Vedantam S, Buchkovich ML, Yang J, Croteau-Chonka DC, Esko T, Fall T, Ferreira T, Gustafsson S, Kutalik Z, Luan J, Magi R, Randall JC, Winkler TW, Wood AR, Workalemahu T, Faul JD, Smith JA, Zhao JH, Zhao W, Chen J, Fehrmann R, Hedman AK, Karjalainen J, Schmidt EM, Absher D, Amin N, Anderson D, Beekman M, Bolton JL, Bragg-Gresham JL, Buyske S, Demirkan A, Deng G, Ehret GB, Feenstra B, Feitosa MF, Fischer K, Goel A, Gong J, Jackson AU, Kanoni S, Kleber ME, Kristiansson K, Lim U, Lotay V, Mangino M, Leach IM, Medina-Gomez C, Medland SE, Nalls MA, Palmer CD, Pasko D, Pechlivanis S, Peters MJ, Prokopenko I, Shungin D, Stancakova A, Strawbridge RJ, Sung YJ, Tanaka T, Teumer A, Trompet S, van der Laan SW, van Setten J, Van Vliet-Ostaptchouk JV, Wang Z, Yengo L, Zhang W, Isaacs A, Albrecht E, Arnlov J, Arscott GM, Attwood AP, Bandinelli S, Barrett A, Bas IN, Bellis C, Bennett AJ, Berne C, Blagieva R, Bluher M, Bohringer S, Bonnycastle LL, Bottcher Y, Boyd HA, Bruinenberg M, Caspersen IH, Chen YI, Clarke R, Daw EW, de Craen AJM, Delgado G, Dimitriou M, Doney ASF, Eklund N, Estrada K, Eury E, Folkersen L, Fraser RM, Garcia ME, Geller F, Giedraitis V, Gigante B, Go AS, Golay A, Goodall AH, Gordon SD, Gorski M, Grabe HJ, Grallert H, Grammer TB, Grassler J, Gronberg H, Groves CJ, Gusto G, Haessler J, Hall P, Haller T, Hallmans G, Hartman CA, Hassinen M, Hayward C, Heard-Costa NL, Helmer Q, Hengstenberg C, Holmen O, Hottenga JJ, James AL, Jeff JM, Johansson A, Jolley J, Juliusdottir T, Kinnunen L, Koenig W, Koskenvuo M, Kratzer W, Laitinen J, Lamina C, Leander K, Lee NR, Lichtner P, Lind L, Lindstrom J, Lo KS, Lobbens S, Lorbeer R, Lu Y, Mach F, Magnusson PKE, Mahajan A, McArdle WL, McLachlan S, Menni C, Merger S, Mihailov E, Milani L, Moayyeri A, Monda KL, Morken MA, Mulas A, Muller G, Muller-Nurasyid M, Musk AW, Nagaraja R, Nothen MM, Nolte IM, Pilz S, Rayner NW, Renstrom F, Rettig R, Ried JS, Ripke S, Robertson NR, Rose LM, Sanna S, Scharnagl H, Scholtens S, Schumacher FR, Scott WR, Seufferlein T, Shi J, Smith AV, Smolonska J, Stanton AV, Steinthorsdottir V, Stirrups K, Stringham HM, Sundstrom J, Swertz MA, Swift AJ, Syvanen AC, Tan ST, Tayo BO, Thorand B, Thorleifsson G, Tyrer JP, Uh HW, Vandenput L, Verhulst FC, Vermeulen SH,

Verweij N, Vonk JM, Waite LL, Warren HR, Waterworth D, Weedon MN, Wilkens LR, Willenborg C, Wilsgaard T, Wojczynski MK, Wong A, Wright AF, Zhang Q, LifeLines Cohort S, Brennan EP, Choi M, Dastani Z, Drong AW, Eriksson P, Franco-Cereceda A, Gadin JR, Gharavi AG, Goddard ME, Handsaker RE, Huang J, Karpe F, Kathiresan S, Keildson S, Kiryluk K, Kubo M, Lee JY, Liang L, Lifton RP, Ma B, McCarroll SA, McKnight AJ, Min JL, Moffatt MF, Montgomery GW, Murabito JM, Nicholson G, Nyholt DR, Okada Y, Perry JRB, Dorajoo R, Reinmaa E, Salem RM, Sandholm N, Scott RA, Stolk L, Takahashi A, Tanaka T, van 't Hooft FM, Vinkhuyzen AAE, Westra HJ, Zheng W, Zondervan KT, Consortium AD, Group A-BW, Consortium CAD, Consortium CK, Glgc, Icbp, Investigators M, Mu TC, Consortium MI, Consortium P, ReproGen C, Consortium G, International Endogene C, Heath AC, Arveiler D, Bakker SJL, Beilby J, Bergman RN, Blangero J, Bovet P, Campbell H, Caulfield MJ, Cesana G, Chakravarti A, Chasman DI, Chines PS, Collins FS, Crawford DC, Cupples LA, Cusi D, Danesh J, de Faire U, den Ruijter HM, Dominiczak AF, Erbel R, Erdmann J, Eriksson JG, Farrall M, Felix SB, Ferrannini E, Ferrieres J, Ford I, Forouhi NG, Forrester T, Franco OH, Gansevoort RT, Gejman PV, Gieger C, Gottesman O, Gudnason V, Gyllensten U, Hall AS, Harris TB, Hattersley AT, Hicks AA, Hindorff LA, Hingorani AD, Hofman A, Homuth G, Hovingh GK, Humphries SE, Hunt SC, Hypponen E, Illig T, Jacobs KB, Jarvelin MR, Jockel KH, Johansen B, Jousilahti P, Jukema JW, Jula AM, Kaprio J, Kastelein JJP, Keinanen-Kiukaanniemi SM, Kiemeney LA, Knekt P, Kooner JS, Kooperberg C, Kovacs P, Kraja AT, Kumari M, Kuusisto J, Lakka TA, Langenberg C, Marchand LL, Lehtimaki T, Lyssenko V, Mannisto S, Marette A, Matise TC, McKenzie CA, McKnight B, Moll FL, Morris AD, Morris AP, Murray JC, Nelis M, Ohlsson C, Oldehinkel AJ, Ong KK, Madden PAF, Pasterkamp G, Peden JF, Peters A, Postma DS, Pramstaller PP, Price JF, Qi L, Raitakari OT, Rankinen T, Rao DC, Rice TK, Ridker PM, Rioux JD, Ritchie MD, Rudan I, Salomaa V, Samani NJ, Saramies J, Sarzynski MA, Schunkert H, Schwarz PEH, Sever P, Shuldiner AR, Sinisalo J, Stolk RP, Strauch K, Tonjes A, Tregouet DA, Tremblay A, Tremoli E, Virtamo J, Vohl MC, Volker U, Waeber G, Willemsen G, Witteman JC, Zillikens MC, Adair LS, Amouyel P, Asselbergs FW, Assimes TL, Bochud M, Boehm BO, Boerwinkle E, Bornstein SR, Bottinger EP, Bouchard C, Cauchi S, Chambers JC, Chanock SJ, Cooper RS, de Bakker PIW, Dedoussis G, Ferrucci L, Franks PW, Froguel P, Groop LC, Haiman CA, Hamsten A, Hui J, Hunter DJ, Hveem K, Kaplan RC, Kivimaki M, Kuh D, Laakso M, Liu Y, Martin NG, Marz W, Melbye M, Metspalu A, Moebus S, Munroe PB, Njolstad I, Oostra BA, Palmer CNA, Pedersen NL, Perola M, Perusse L, Peters U, Power C, Quertermous T, Rauramaa R, Rivadeneira F, Saaristo TE, Saleheen D, Sattar N, Schadt EE, Schlessinger D, Slagboom PE, Snieder H, Spector TD, Thorsteinsdottir U, Stumvoll M, Tuomilehto J, Uitterlinden AG, Uusitupa M, van der Harst P, Walker M, Wallaschofski H, Wareham NJ, Watkins H, Weir DR, Wichmann HE, Wilson JF, Zanen P, Borecki IB, Deloukas P, Fox CS, Heid IM, O'Connell JR, Strachan DP, Stefansson K, van Duijn CM, Abecasis GR, Franke L, Frayling TM, McCarthy MI, Visscher PM, Scherag A, Willer CJ, Boehnke M, Mohlke KL, Lindgren CM, Beckmann JS, Barroso I, North KE, Ingelsson E, Hirschhorn JN, Loos RJF, Speliotes EK. Genetic studies of body mass index yield new insights for obesity biology. Nature 2015;518:197-206

12. Shungin D, Winkler TW, Croteau-Chonka DC, Ferreira T, Locke AE, Magi R, Strawbridge RJ, Pers TH, Fischer K, Justice AE, Workalemahu T, Wu JMW, Buchkovich ML, Heard-Costa NL, Roman TS, Drong AW, Song C, Gustafsson S, Day FR, Esko T, Fall T, Kutalik Z, Luan J, Randall JC, Scherag A, Vedantam S, Wood AR, Chen J, Fehrmann R, Karjalainen J, Kahali B, Liu CT, Schmidt EM, Absher D, Amin N, Anderson D, Beekman M, Bragg-Gresham JL, Buyske S, Demirkan A, Ehret GB, Feitosa MF, Goel A, Jackson AU, Johnson T, Kleber ME, Kristiansson K, Mangino M, Leach IM, Medina-Gomez C, Palmer CD, Pasko D, Pechlivanis S, Peters MJ, Prokopenko I, Stancakova A, Sung YJ, Tanaka T, Teumer A, Van Vliet-Ostaptchouk JV, Yengo L, Zhang W, Albrecht E, Arnlov J, Arscott GM, Bandinelli S, Barrett A, Bellis C, Bennett AJ, Berne C, Bluher M, Bohringer S, Bonnet F, Bottcher Y, Bruinenberg M, Carba DB, Caspersen IH, Clarke R, Daw EW, Deelen J, Deelman E, Delgado G, Doney AS, Eklund N, Erdos MR, Estrada K, Eury E, Friedrich N, Garcia ME, Giedraitis V, Gigante B, Go AS, Golay A, Grallert H, Grammer TB, Grassler J, Grewal J, Groves CJ, Haller T, Hallmans G, Hartman CA, Hassinen M, Hayward C, Heikkila K, Herzig KH, Helmer Q, Hillege HL, Holmen O, Hunt SC, Isaacs A, Ittermann T, James AL, Johansson I, Juliusdottir T, Kalafati IP, Kinnunen L, Koenig W, Kooner IK, Kratzer W, Lamina C, Leander K, Lee NR, Lichtner P, Lind L, Lindstrom J, Lobbens S, Lorentzon M, Mach F, Magnusson PK, Mahajan A, McArdle WL, Menni C, Merger S, Mihailov E, Milani L, Mills R, Moayyeri A, Monda KL, Mooijaart SP, Muhleisen TW, Mulas A, Muller G, Muller-Nurasyid M, Nagaraja R, Nalls MA, Narisu N, Glorioso N, Nolte IM, Olden M, Rayner NW, Renstrom F, Ried JS, Robertson NR, Rose LM, Sanna S, Scharnagl H, Scholtens S, Sennblad B, Seufferlein T, Sitlani CM, Smith AV, Stirrups K, Stringham HM, Sundstrom J, Swertz MA, Swift AJ, Syvanen AC, Tayo BO, Thorand B, Thorleifsson G, Tomaschitz A, Troffa C, van Oort FV, Verweij N, Vonk JM, Waite LL, Wennauer R, Wilsgaard T, Wojczynski MK, Wong A, Zhang Q, Zhao JH, Brennan EP, Choi M, Eriksson P, Folkersen L, Franco-Cereceda A, Gharavi AG, Hedman AK, Hivert MF, Huang J, Kanoni S, Karpe F, Keildson S, Kiryluk K, Liang L, Lifton RP, Ma B, McKnight AJ, McPherson R, Metspalu A, Min JL, Moffatt MF, Montgomery GW, Murabito JM, Nicholson G, Nyholt DR, Olsson C, Perry JR, Reinmaa E, Salem RM, Sandholm N, Schadt EE, Scott RA, Stolk L, Vallejo EE, Westra HJ, Zondervan KT, Consortium AD, Consortium CAD, Consortium CK, Consortium G, Consortium G, Glgc, Icbp, International Endogene C,

LifeLines Cohort S, Investigators M, Mu TC, Consortium P, ReproGen C, Amouyel P, Arveiler D, Bakker SJ, Beilby J, Bergman RN, Blangero J, Brown MJ, Burnier M, Campbell H, Chakravarti A, Chines PS, Claudi-Boehm S, Collins FS, Crawford DC, Danesh J, de Faire U, de Geus EJ, Dorr M, Erbel R, Eriksson JG, Farrall M, Ferrannini E, Ferrieres J, Forouhi NG, Forrester T, Franco OH, Gansevoort RT, Gieger C, Gudnason V, Haiman CA, Harris TB, Hattersley AT, Heliovaara M, Hicks AA, Hingorani AD, Hoffmann W, Hofman A, Homuth G, Humphries SE, Hypponen E, Illig T, Jarvelin MR, Johansen B, Jousilahti P, Jula AM, Kaprio J, Kee F, Keinanen-Kiukaanniemi SM, Kooner JS, Kooperberg C, Kovacs P, Kraja AT, Kumari M, Kuulasmaa K, Kuusisto J, Lakka TA, Langenberg C, Le Marchand L, Lehtimaki T, Lyssenko V, Mannisto S, Marette A, Matise TC, McKenzie CA, McKnight B, Musk AW, Mohlenkamp S, Morris AD, Nelis M, Ohlsson C, Oldehinkel AJ, Ong KK, Palmer LJ, Penninx BW, Peters A, Pramstaller PP, Raitakari OT, Rankinen T, Rao DC, Rice TK, Ridker PM, Ritchie MD, Rudan I, Salomaa V, Samani NJ, Saramies J, Sarzynski MA, Schwarz PE, Shuldiner AR, Staessen JA, Steinthorsdottir V, Stolk RP, Strauch K, Tonjes A, Tremblay A, Tremoli E, Vohl MC, Volker U, Vollenweider P, Wilson JF, Witteman JC, Adair LS, Bochud M, Boehm BO, Bornstein SR, Bouchard C, Cauchi S, Caulfield MJ, Chambers JC, Chasman DI, Cooper RS, Dedoussis G, Ferrucci L, Froguel P, Grabe HJ, Hamsten A, Hui J, Hveem K, Jockel KH, Kivimaki M, Kuh D, Laakso M, Liu Y, Marz W, Munroe PB, Njolstad I, Oostra BA, Palmer CN, Pedersen NL, Perola M, Perusse L, Peters U, Power C, Quertermous T, Rauramaa R, Rivadeneira F, Saaristo TE, Saleheen D, Sinisalo J, Slagboom PE, Snieder H, Spector TD, Stefansson K, Stumvoll M, Tuomilehto J, Uitterlinden AG, Uusitupa M, van der Harst P, Veronesi G, Walker M, Wareham NJ, Watkins H, Wichmann HE, Abecasis GR, Assimes TL, Berndt SI, Boehnke M, Borecki IB, Deloukas P, Franke L, Frayling TM, Groop LC, Hunter DJ, Kaplan RC, O'Connell JR, Qi L, Schlessinger D, Strachan DP, Thorsteinsdottir U, van Duijn CM, Willer CJ, Visscher PM, Yang J, Hirschhorn JN, Zillikens MC, McCarthy MI, Speliotes EK, North KE, Fox CS, Barroso I, Franks PW, Ingelsson E, Heid IM, Loos RJ, Cupples LA, Morris AP, Lindgren CM, Mohlke KL. New genetic loci link adipose and insulin biology to body fat distribution. Nature 2015;518:187-196

13. Initiative C-HG. The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic. Eur J Hum Genet 2020;28:715-718

14. Burgess S. Sample size and power calculations in Mendelian randomization with a single instrumental variable and a binary outcome. Int J Epidemiol 2014;43:922-929

15. Caussy C, Pattou F, Wallet F, Simon C, Chalopin S, Telliam C, Mathieu D, Subtil F, Frobert E, Alligier M, Delaunay D, Vanhems P, Laville M, Jourdain M, Disse E, Consortium COH, Lille C-OSG. Prevalence of obesity among adult inpatients with COVID-19 in France. Lancet Diabetes Endocrinol 2020;8:562-564

16. Wang Y, Pan B, Liu Y, Wilson A, Ou J, Chen R. Health care and mental health challenges for transgender individuals during the COVID-19 pandemic. Lancet Diabetes Endocrinol 2020;8:564-565

17. Reilly SM, Saltiel AR. Adapting to obesity with adipose tissue inflammation. Nat Rev Endocrinol 2017;13:633-643

18. Lackey DE, Olefsky JM. Regulation of metabolism by the innate immune system. Nat Rev Endocrinol 2016;12:15-28

19. Green WD, Beck MA. Obesity Impairs the Adaptive Immune Response to Influenza Virus. Ann Am Thorac Soc 2017;14:S406-S409

20. Honce R, Schultz-Cherry S. Impact of Obesity on Influenza A Virus Pathogenesis, Immune Response, and Evolution. Front Immunol 2019;10:1071

21. Hoffmann M, Kleine-Weber H, Pohlmann S. A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells. Mol Cell 2020;78:779-784 e775

22. Engeli S, Schling P, Gorzelniak K, Boschmann M, Janke J, Ailhaud G, Teboul M, Massiera F, Sharma AM. The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome? Int J Biochem Cell Biol 2003;35:807-825

23. Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, Huan Y, Yang P, Zhang Y, Deng W, Bao L, Zhang B, Liu G, Wang Z, Chappell M, Liu Y, Zheng D, Leibbrandt A, Wada T, Slutsky AS, Liu D, Qin C, Jiang C, Penninger JM. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury. Nature Medicine 2005;11:875-879

24. Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, Yang P, Sarao R, Wada T, Leong-Poi H, Crackower MA, Fukamizu A, Hui C-C, Hein L, Uhlig S, Slutsky AS, Jiang C, Penninger JM. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 2005;436:112-116

25. Akoumianakis I, Filippatos T. The renin-angiotensin-aldosterone system as a link between obesity and coronavirus disease 2019 severity. Obes Rev 2020;

26. Semenza JC, Lindgren E, Balkanyi L, Espinosa L, Almqvist MS, Penttinen P, Rocklov J. Determinants and Drivers of Infectious Disease Threat Events in Europe. Emerg Infect Dis 2016;22:581-589

Table 1 Mendelian randomization estimates for the association between body mass index (BMI), waist circumference (WC), and waist-to-hip ratio (WHR) related Single Nucleotide Polymorphisms (SNPs) and COVID-19 susceptibility

Method	nsnp	OR	95 % CI	P-value	Exposure
Inverse variance weighted (multiplicative random effects)	68	1.408	(1.154-1.718)	0.001	BMI
Weighted median	68	1.327	(0.958-1.839)	0.089	BMI
Weighted mode	68	1.250	(0.717-2.180)	0.435	BMI
Radial_IVW_(Mod.2nd)	68	1.408	(1.154-1.718)	0.001	BMI
Radial_IVW_exact_FE	68	1.415	(1.130-1.772)	0.003	BMI
Radial_IVW_exact_RE	68	1.415	(1.160-1.727)	0.001	BMI
RAPS	68	1.415	(1.125-1.781)	0.003	BMI
PRESSO_raw	68	1.408	(1.154-1.718)	0.001	BMI
Inverse variance weighted (multiplicative random effects)	41	1.377	(1.065-1.780)	0.015	WC
Weighted median	41	1.362	(0.925-2.006)	0.117	WC
Weighted mode	41	1.296	(0.658-2.556)	0.458	WC
Radial_IVW_(Mod.2nd)	41	1.377	(1.065-1.780)	0.015	WC
Radial_IVW_exact_FE	41	1.384	(1.040-1.843)	0.026	WC
Radial_IVW_exact_RE	41	1.384	(1.088-1.761)	0.012	WC
RAPS	41	1.384	(1.033-1.855)	0.029	WC
PRESSO_raw	41	1.377	(1.065-1.780)	0.019	WC
Inverse variance weighted (multiplicative random effects)	27	1.217	(0.933-1.589)	0.148	WHR
Weighted median	27	1.065	(0.632-1.797)	0.812	WHR
Weighted mode	27	1.104	(0.501-2.432)	0.808	WHR
Radial_IVW_(Mod.2nd)	27	1.217	(0.933-1.589)	0.148	WHR
Radial_IVW_exact_FE	27	1.220	(0.844-1.764)	0.291	WHR
Radial_IVW_exact_RE	27	1.220	(0.948-1.570)	0.134	WHR
RAPS	27	1.220	(0.835-1.782)	0.304	WHR
PRESSO_raw	27	1.217	(0.933-1.589)	0.160	WHR

Abbrevations: OR, odds ratio; CI, confidence interval.

Table 2 Mendelian randomization estimates for the association between body mass index (BMI), waist circumference (WC), and waist-to-hip ratio (WHR) related Single Nucleotide Polymorphisms (SNPs) and hospitalization due to severity of COVID-19 disease

Method	nsnp	OR	95 % CI	P-value	Exposure
Inverse variance weighted (multiplicative random effects)	68	1.596	(1.187-2.144)	0.002	BMI
Weighted median	68	1.648	(1.006-2.701)	0.047	BMI
Weighted mode	68	0.997	(0.407-2.441)	0.995	BMI
Radial_IVW_(Mod.2nd)	68	1.596	(1.187-2.144)	0.002	BMI
Radial_IVW_exact_FE	68	1.606	(1.154-2.235)	0.005	BMI
Radial_IVW_exact_RE	68	1.606	(1.218-2.117)	0.001	BMI
RAPS	68	1.606	(1.146-2.250)	0.006	BMI
PRESSO_raw	68	1.596	(1.187-2.144)	0.003	BMI
Inverse variance weighted (multiplicative random effects)	41	1.472	(0.971-2.232)	0.069	WC
Weighted median	41	1.441	(0.781-2.656)	0.242	WC
Weighted mode	41	1.240	(0.463-3.323)	0.671	WC
Radial_IVW_(Mod.2nd)	41	1.472	(0.971-2.232)	0.069	WC
Radial_IVW_exact_FE	41	1.483	(0.971-2.265)	0.068	WC
Radial_IVW_exact_RE	41	1.483	(0.996-2.208)	0.059	WC
RAPS	41	1.483	(0.962-2.285)	0.074	WC
PRESSO_raw	41	1.472	(0.971-2.232)	0.076	WC
Inverse variance weighted (multiplicative random effects)	27	1.164	(0.713-1.899)	0.544	WHR
Weighted median	27	0.965	(0.460-2.022)	0.924	WHR
Weighted mode	27	0.585	(0.156-2.198)	0.434	WHR
Radial_IVW_(Mod.2nd)	27	1.164	(0.713-1.899)	0.544	WHR
Radial_IVW_exact_FE	27	1.167	(0.685-1.989)	0.571	WHR
Radial_IVW_exact_RE	27	1.167	(0.708-1.924)	0.550	WHR
RAPS	27	1.167	(0.675-2.016)	0.580	WHR
PRESSO_raw	27	1.164	(0.713-1.899)	0.549	WHR

Abbrevations: OR, odds ratio; CI, confidence interval.

Figure 1 Causal estimates (odds ratios and 95 % confidence intervals) of body mass index (BMI), waist circumference (WC), and waist-to-hip ratio (WHR) with COVID-19 susceptibility and hospitalization. Grey points with dashed confidence intervals correspond to estimates biased regarding the influential SNP rs12549058.